Chapter 26 Multiple sclerosis
With contribution from Dr Lily Tomas
Introduction
Multiple sclerosis (MS) is the most common progressive, neurological disorder in most Western countries today.1 It is an auto-immune, inflammatory, demyelinating condition of the central nervous system (CNS) that has no known cure.2 Despite the incredible progress that has been made with modern medicine, the treatment of MS with pharmaceuticals is certainly not ideal. Presumably for this reason, many people with MS worldwide are actively involved in self-care, using complementary and alternative medicine (CAM) therapies to help with symptom management.3, 4
A recent review of the literature demonstrates that the primary reasons for choosing CAM include the desire to use an holistic health care approach, conventional treatment not being effective, anecdotal reports of CAM efficacy and doctor referral. It is interesting to note that many people also choose CAM because they were unsatisfied with their initial consultation with their physician lasting less than 15 minutes.5, 6 The major symptoms being treated with CAM include pain, fatigue and stress, with the major therapies being dietary modification, nutritional and herbal supplementation, exercise, cold baths and mind–body therapies.4, 7, 8
Use of CAM therapies has been associated with religiosity, functional independence, female sex, white-collar jobs and higher education. Compared with conventional treatments, CAM therapies also rarely have unwanted side-effects (9% vs 59%).5
MS is a complex disease, perhaps encompassing more than a single aetiopathological entity and very likely subject to multi-factorial aetiology9 with ample evidence revealing an intricate interplay from genetics and differing environmental factors. Current research strongly indicates that previous infection with Epstein-Barr virus, vitamin D deficiency and smoking are major risk factors for developing this most debilitating and unpredictable disorder.10–14 Furthermore, it has been shown that good nutrition, sunlight exposure, exercise, stress and social factors can all influence the rate of progression and the level of disability.1
MS has always been considered to be more common in women and in areas further from the equator. However, recent reports indicate that the female:male ratio has increased and the latitude gradient decreased in the last 5 decades.15
Lifestyle — general
It is well documented that lifestyle approaches may significantly influence the development and progression of MS, and hence offer potentially effective avenues for therapy.1
Patients with MS have frequent adverse health behaviours, such as lack of outdoor exercise, smoking and drinking alcohol, which increase the risk of other chronic diseases. Further research is required to determine the extent of such behaviours on the progression of MS.18
Mind–body medicine
As we are all aware, stress can exacerbate many pathophysiogical disease processes, including those of neurodenerative origin.19
Corticotropin-releasing hormone (CRH) plays a central role in the regulation of the hypothalamic–pituitary–adrenal (HPA) axis; that is, the common final pathway in the stress response.20 Patients with MS have also been demonstrated to have HPA axis hyperactivity, therefore stress-relieving activities are considered to be particularly beneficial in this population.21
The discipline of psychoneuroimmunology has demonstrated that the immune system most certainly interacts with the CNS.22
A recent RCT has shown that telephone counselling for those with MS significantly improves physical activity, spiritual growth, stress management, fatigue and general mental health status compared with controls. There was also greater improvement in walking speed in those who chose to exercise more.23
As previously stated, fatigue is a frequent and disabling symptom in those with MS. Underlying psychological processes may certainly be part of this aetiology.24 It has been shown that a challenging mental task can alter the pattern and increase the cerebral activation on an unrelated motor task in fatigued MS patients.25, 26
Cognitive behaviour therapy (CBT) rehabilitation in MS is in its relative infancy.27 A recent Cochrane review has indicated that there is adversity of psychological interventions that can potentially help those with MS. CBT approaches, in particular, are beneficial in the treatment of depression, and in helping people adjust to, and cope with, having MS.28 A recent Australian longitudinal assessment study of anxiety, depression and fatigue in MS has confirmed this finding.29
Sleep
Fatigue is one of the most common symptoms of MS. The mechanisms underlying such fatigue are still poorly understood and are obviously multifactorial. Eliminating sleep disorders (as well as adverse drug effects, infections, iron/vitamin B12 deficiency) is an important part of an MS work-up.30, 31, 32 The prevalence of sleep problems in MS is significantly higher than in the general population and mostly affects women with MS more than men.33
Restless legs syndrome (RLS) is also significantly associated with MS, especially in patients with severe pyramidal and sensory disability. RLS is known to have a significant impact on sleep quality in patients with MS, and as such, a thorough history regarding this should always be taken.34 Patients with RLS present with greater disability and greater levels of fatigue.35 Anecdotal evidence strongly suggests that magnesium can assist with RLS. Restoring sleep patterns may help reduce symptoms of MS.
Sunshine
Sunlight exposure has emerged as being the most likely candidate for the explanations in geographical variations in MS prevalence; that is, increased risk of MS in populations residing at higher or lower latitudes.36 This observation implies a protective effect of sunlight, which is reduced at higher or lower latitudes, contributing to insufficient levels of vitamin D that are frequently found in those with MS.37
Monthly variations in MS relapses (with more relapses occurring in colder months) have been recently documented in Australia. Relapse rates were therefore inversely associated with UV radiation and serum 25(OH)D levels and positively associated with upper respiratory tract infections.38
Australian research has also demonstrated that those individuals with fair skin/red hair have an increased risk of MS that is more evident in women. As a child, they tended to behaviourally avoid sun exposure. In contrast, increased sun exposure from ages 6–10 is associated with reduced MS risk in those individuals without red hair. It should be noted, however, that the interplay between melanocortin 1 receptor variants, red hair/fair skin phenotype, past sun exposure and MS is complex.39
Earlier studies have also shown that increased outdoor activities during summer in early life even north of the Arctic circle are associated with a reduced risk of developing MS; most pronounced age range being 16–20 years.40, 41
Adverse reports of high ambient temperatures in people with MS correlate significantly with the report of strong sunlight, apparently making MS worse. This appears to be worse with increasing age. In Australia, high temperatures are more likely to be reported as adverse in warmer, lower latitude regions. This apparent adverse factor therefore appears to be related to solar heat, not solar light.8
Environmental influences
Geographical patterns in Australia currently imply that modifiable environmental factors hold the key to preventing approximately 80% of MS cases. Genetic epidemiology demonstrates that family history has an important role. However, if these factors are held constant, the environment sets the disease threshold.42
Recent studies have shown that men develop MS at lower levels of environmental exposure than women. Women, however, appear to be more responsive to the recent changes in environmental exposure that have seen a change in the sex ratio prevalence of MS in recent decades.43
Epstein-Barr virus (EBV)
Data from studies of twins and migrants with MS certainly imply environmental factors in the development of MS.44 There is a wealth of evidence linking EBV with MS, with the viral infection having potential roles in both initiating the auto-immune process and exacerbating disease progression.12, 43, 45–48 Furthermore, there is evidence to suggest that there is infection with EBV in brain lesions of MS patients.49 There is nearly a 100% sero-prevalence to EBV antibodies in MS years before clinical onset of the disease.44, 49 It appears that individuals with EBV Nuclear antigen 1 (EBNA-1) have a 2.8 times increased risk of developing MS, independently from DR15 allele.49 Carriers of this allele who also have elevated anti-EBNA-1 titres may have a significantly increased risk of MS.50 Amongst those who develop MS, antibody titres were 2–3 times higher in those individual who were 25 years of age or higher, suggesting an age-dependent relationship between EBV and MS.51 The risk is also increased after an initial symptomatic EBV infection.44
There is also recent evidence to suggest that Chlamydia pneumonia, which belongs to the rickettsial family of micro-organisms, is also linked to MS.52
Smoking
As stated previously, there is a multitude of studies demonstrating an association between smoking and MS.53, 54 Those who begin smoking at an early age are significantly more likely to develop progressive MS at an early age compared with later debut smokers or non-smokers.55
Furthermore, modestly elevated cotinine levels suggestive of passive smoking are also associated with an increased risk for MS.56, 57
Smoking during the cohort period was not associated with relapse.58
Thus far, smoking during pregnancy has not been shown to be a risk for early-onset MS amongst offspring.59
Heavy metal exposure
There is an observable difference in MS prevalence in particular regions with perceived clusters of MS throughout several countries. Such clusters have occurred around lead smelters, oil refineries and air pollutants. No direct associations have as yet been made.60–63
In contrast to immunoglobulins (IgGs) of healthy individuals, antibodies of MS patients effectively hydrolyse human myelin basic protein (MBP). Furthermore, IgG from sera of MS patients have been shown to possess metal-dependent human MBP-hydrolysing activity.64
Iron overload and the upregulation of iron-binding proteins in the brain have also been implicated in the pathogenesis of MS.65 Indeed, MRIs reveal significant and pathological iron deposition in brain MS lesions.66, 67 Urinary concentrations of iron are significantly increased in secondary progressive MS and insignificantly increased in relapsing–remitting MS (RRMS). This increased urinary iron excretion supports a role for iron dysmetabolism in MS.68 Iron imbalance is associated with pro-inflammatory cytokines and oxidative stress, suggesting that the improvement of neuronal iron metabolism may be a future target for MS therapy.65
Similarly, urinary concentrations of aluminium (Al) are also significantly increased in both secondary progressive and relapsing–remitting forms of MS. These levels of urinary Al are high enough to be compared with levels observed in individuals with Al intoxication who are undergoing specific metal chelation therapy. In accordance with this, urinary excretion of silicon is lower in MS and significantly lower in secondary progressive MS. It has since been concluded that Al may be another environmental factor associated with the aetiology of MS. If this is the case, then an increased intake of its natural antagonist, silicon, may be another therapeutic option.68
Individuals with dental amalgam have been shown to have 2–12 times more mercury in their body tissues than those without. Mercury deposits in brain and bone tissues have a half-life lasting from several years to decades and may accumulate over time of exposure.69 A recent systematic review and meta-analysis was performed in order to investigate the possible association between methyl mercury in dental amalgam and MS. The pooled odds ratios for the risk of MS amongst those with amalgams was consistent with a slight non–statistically significant increase between amalgam use and risk of MS. Further studies regarding amalgam restoration size and duration of exposure are needed to definitively rule out any link between amalgam and MS.70
Studies have also shown that Tetrathiomolybdate (TM), a potent anti-copper drug, significantly inhibits neurological damage associated with animal models of MS. TM also strongly suppresses increases in inflammatory and immune-related cytokines, reducing oxidative stress significantly.71
Physical activities
Exercise
The cumulative evidence supports the idea that exercise training is associated with an improvement in mobility amongst individuals with MS.72, 73, 74 Current studies indicate that physical activity in MS patients counteracts depression and fatigue and may improve quality of life.75, 76, 77 Aerobic treadmill activity is feasible, safe and may improve anomalies of posture and gait in early MS patients.78 Physical activity can certainly adapt and manipulate neuronal connections and synaptic activity with natural killer (NK) cells having been shown to be the most responsive immune cell to acute exercise.79, 80
Physicians should be encouraged to promote individualised strategies which enhance ‘perceived control over fatigue’ and ‘listening to your body’ in order to maximise the benefits of exercise intervention for individuals with MS-related fatigue.81 As such, it is difficult to prescribe a generalised regular exercise prescription for all those suffering with MS.82
Heat reactions are common in MS, such that exposure to heat may consequently result in the appearance of neurological signs. Exercise is one means that is known to increase basal body temperature. It is as yet not understood if or why thermal heat induces central fatigue in patients with MS, however, this is subjectively reported as a common phenomenon.83
One recent study involving MS patients who performed acute cycling has demonstrated that moderate intensity exercise was associated with reductions in anxiety and general mood disturbances. Such changes are noted to be greater in those with higher baseline anxiety.84
Exercise therapy was also noted to be beneficial for patients with MS not experiencing a relapse in a 2005 Cochrane review.85
RCTs investigating the effects of functional electrical stimulation suggest that this may also provide an orthotic benefit to those suffering with MS.86, 87
Further studies are still required as to the effects of whole body vibration therapy on muscle performance in people with MS.88
Nutritional influences
Diet
Diets and dietary supplements are widely used by people with MS in order to improve disease outcomes. Clinical data has suggested that certain dietary regimes may be beneficial in MS. However, a recent Cochrane review states that more research is needed to assess the efficacy of dietary interventions in MS.90
Caloric restriction
It is thought that caloric restriction with adequate nutrition under diligent medical supervision should be explored as a potential treatment for MS as it induces anti-inflammatory, antioxidant and neuroprotective effects that may be beneficial.91, 92
Fish intake
The risk of developing MS has been associated with an increased dietary intake of saturated fatty acids.93 A recent study has indicated that a diet rich in salmon (3–4 times weekly) may provide a protective role in demyelination.40 This is believed to be secondary to the omega-3 polyunsaturated fatty acids (PUFA) content as no protective effect was observed with a cod-liver oil-based diet.94, 95 It is important to note, however, that cod-liver oil supplementation may provide some protection.40 Norway appears to be a discrete exception to the prevalence of MS in higher latitudes. UV exposure is low in this country, however, vitamin D sufficiency is maintained through a traditional diet providing vitamin D as well as marine omega-3 PUFAs.96 Indeed, recent results suggest that a low fat diet supplemented with omega-3 PUFAs may become the standard recommended therapy for those with MS.97
Artificial sweeteners
There is currently controversy regarding the potential toxicity of low-calorie artificial sweeteners such as aspartame, acesulfame-K (ASK) and saccharin and their possible relationship to MS. Animal studies have shown that the genotoxic potential of ASK and saccharin is greater than aspartame (ASP). However, none could act as a potential mutagen alone. These findings are important as they represent a potential health risk associated with exposure to these agents.98, 99
Gluten
MS and coeliac disease are both considered to be T-cell mediated auto-immune diseases. It has been postulated that the interaction of MS and coeliac disease inflammatory processes may result in an amplification of Th1 response.100 There is some evidence that individuals with MS have highly significant increases of IgA and IgG antibodies against gliadin and gluten and significant increases against casein (cow’s milk) compared with controls. It should be noted that anti-endomycium and anti-transglutaminase antibodies were negative.101, 102 Recent studies, however, have conflicting data, showing that gluten sensitivity is not associated with MS.103, 104
Nutritional supplementation
Vitamin D
Supplementation with vitamin D is considered to be necessary in northern and southern latitudes to maintain adequate levels of 25(OH)D3 for optimal health and disease prevention.105 This is certainly understandable, however, it is imperative to note that vitamin D insufficiency is also very common across a wide latitude range in Australia.
current Australian sun exposure guidelines do not seem to fully prevent vitamin D insufficiency, and consideration should be given to their modification or to pursuing other mean to achieve vitamin D adequacy.106
There has been a multitude of recent studies linking low levels of vitamin D with an increased risk of MS. Initial research centred around the striking prevalence of MS in populations residing at higher latitudes. The protective effect of sunlight is reduced at these latitudes, subsequently leading to insufficiencies in vitamin D. Vitamin D is a hormone now known to be involved in far more than the protection of bones. It can regulate processes of cell proliferation, differentiation and apoptosis important in cancer prevention and can profoundly affect both the innate and adaptive immune systems providing protection against certain immune-mediated disorders.107, 108, 109
Recent genetic studies have also revealed important vitamin D receptor gene polymorphisms, highlighting once again the complex interaction between genetics and environment.96, 110, 111 There is strong evidence that vitamin D is an important modifiable environmental/nutritional factor in the pathogenesis of MS with a potential role in its prevention and/or treatment.37, 107, 112
Epidemiological evidence supports the view that vitamin D metabolites have significant immune and disease-modulating effects in MS. Vitamin D mediates a shift to a more anti-inflammatory immune response and enhances regulatory T-cell functionality.113 As such, vitamin D plays an important role in T-cell homeostasis during the course of MS and correcting low levels may be useful during treatment of this disease.114
A recent hypothesis suggests that lack of sunlight exposure and viral infections such as herpes and EBV may synergistically induce a defect in IL-10-producing regulatory lymphocytes that may undermine self-tolerance mechanisms and hence enable a pathogenic autoimmune response to neural proteins.115
Low serum vitamin D3 levels correlate strongly with MS risk and have been well documented in many studies.115, 116 Lower levels are seen in RRMS compared with progressive MS patients and controls, particularly during relapses.114 Lower circulating levels of 25(OH)D have since been found to be particularly associated with higher MS-related disability in women.117
Supplementation with the active form of vitamin D to animal models of MS both suppresses disease development and leads to improvement of immune-mediated symptoms.108 Complete disease prevention only occurred with extremely high doses of vitamin D3, such that calcium levels were also significantly elevated. A combination of calcitonin and a smaller dose of vitamin D3, however, synergistically suppressed MS development in animals without causing hypercalcaemia. This finding may become extremely important in the treatment of patients with MS.118
A recent meta-analysis has demonstrated that vitamin D supplementation significantly reduces all-cause mortality, highlighting the medical, ethical and legal implications of promptly diagnosing and treating vitamin D deficiency. Treatment in otherwise healthy patients with vitamin D supplementation should be sufficient to maintain year-round 25(OH)D3 levels at least between 40–70ng/mL. Those vitamin D deficient patients with chronic diseases such as MS often need to be investigated and treated more aggressively so that levels are at least between 55–70ng/mL.116, 119 It is important to note, however, that with increasing knowledge of the importance of vitamin D to health, these reference ranges are likely to be increased in the future.
Long-term supplementation with vitamin D and cod-liver oil has been associated with a decreased incidence of developing MS. Osteoporosis is more common in patients with MS, such that prophylaxis with vitamin D and calcium is widely accepted by most.120, 121, 40 Parathyroid hormone (PTH) levels have been noted to be higher during a relapse of MS and lower during remission and in winter. MS patients also have a relative hypocalcaemia in winter, thus the endocrine circuitry regulating serum calcium is altered in MS.122
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
